Functional wellness brand SuperMush has raised $3 million in Series A funding from NDude Labs, a healthcare and wellness-focused investment firm. The round will support the brand's next phase of growth, including product portfolio expansion, investment in advanced formulations and the operational infrastructure needed to serve a wider customer base.
Founded in 2022 by Alli Schaper and Brian Friedman, SuperMush develops functional wellness products formulated with research-backed ingredients such as nootropics, adaptogens and functional mushrooms. The brand has built an omnichannel retail strategy: its products are available in more than 2,000 retail stores across the United States, including over 1,000 Target locations and Sprouts, alongside a strong direct-to-consumer and marketplace business through its own website and Amazon.
Over the past year, the brand broadened its lineup with the introduction of Shilajit, Creatine and Lion's Mane gummies, leaning into the growing consumer demand for science-backed supplements at meaningful doses. Co-founder and CEO Alli Schaper said the company aims to bring the power of functional mushrooms to the world, while co-founder Brian Friedman said the goal is to become the premium functional supplement brand for active lifestyles.
Vikram Sehgal, COO at NDude Labs, said the firm invests in differentiated, science-backed products and founders with the vision and grit to build enduring brands, adding that the investment provides capital to accelerate growth along with talent, systems and support to scale thoughtfully and sustainably.
The investment follows NDude Labs' recent backing of Nutriventia, a nutraceutical ingredients company, highlighting the firm's continued focus on health and wellness businesses built around science-driven, ingredient-led innovation. The functional wellness and dietary supplements market continues to attract institutional capital as consumers shift towards preventative, ingredient-first health products.
Why it matters for founders
SuperMush shows that ingredient-led differentiation — clinically studied inputs at real doses — is what unlocks institutional wellness capital. Distribution did the heavy lifting here: 1,000+ Target doors prove velocity, which de-risks the next round. If you are building a D2C wellness brand, prioritise one or two hero ingredients with a clear science story before expanding the portfolio; retailers and investors both buy conviction, not catalogue width.